156 related articles for article (PubMed ID: 37823901)
1. Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer.
Tian W; Zhao J; Wang W
Lung; 2023 Oct; 201(5):489-497. PubMed ID: 37823901
[TBL] [Abstract][Full Text] [Related]
2. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
3. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
4. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
6. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
Min JT; Zhang L; Long CR; Fan HL; Li ZZ
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
[No Abstract] [Full Text] [Related]
7. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
Crossland DL; Denning WL; Ang S; Olivares S; Mi T; Switzer K; Singh H; Huls H; Gold KS; Glisson BS; Cooper LJ; Heymach JV
Oncogene; 2018 Jul; 37(27):3686-3697. PubMed ID: 29622795
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer.
Zhong M; Chalbatani GM; Deng M; Li Q; Gharagouzloo E; Hamblin MR; Suarez ER; Hu L; Wang D
Eur J Pharm Sci; 2023 Jan; 180():106331. PubMed ID: 36384203
[TBL] [Abstract][Full Text] [Related]
10. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.
Min J; Long C; Zhang L; Duan J; Fan H; Chu F; Li Z
Bioengineered; 2022 Apr; 13(4):9216-9232. PubMed ID: 35378051
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
Hänsch L; Peipp M; Mastall M; Villars D; Myburgh R; Silginer M; Weiss T; Gramatzki D; Vasella F; Manz MG; Weller M; Roth P
Neuro Oncol; 2023 Nov; 25(11):2001-2014. PubMed ID: 37335916
[TBL] [Abstract][Full Text] [Related]
13. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
14. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
15. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE; Khan JF; Godfrey WD; Lopez AV; Ciampricotti M; Rudin CM; Brentjens RJ
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36951942
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
17. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
18. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
19. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
20. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
